Heron Therapeutics Inc. (NASDAQ:HRTX) shares shot up 4.7% during mid-day trading on Wednesday . The company traded as high as $17.66 and last traded at $17.39, with a volume of 159,212 shares changing hands. The stock had previously closed at $16.61.

A number of brokerages have issued reports on HRTX. Jefferies Group reaffirmed a “buy” rating and issued a $46.00 target price on shares of Heron Therapeutics in a report on Wednesday. Cowen and Company reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Saturday, July 9th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Sunday, May 8th. Noble Financial reaffirmed a “buy” rating and issued a $51.00 target price on shares of Heron Therapeutics in a report on Wednesday, April 20th. Finally, Brean Capital reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Monday, April 18th. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $50.30.

The stock has a 50 day moving average price of $17.79 and a 200 day moving average price of $19.10.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.92). On average, equities analysts forecast that Heron Therapeutics Inc. will post ($3.59) earnings per share for the current year.

A number of hedge funds and institutional investors have recently bought and sold shares of HRTX. California State Teachers Retirement System raised its position in Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock worth $1,447,000 after buying an additional 1,000 shares during the last quarter. GAM Holding AG raised its position in Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock worth $1,119,000 after buying an additional 9,400 shares during the last quarter. Russell Frank Co raised its position in Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock worth $1,369,000 after buying an additional 15,585 shares during the last quarter. Turner Investments L.P. increased its stake in Heron Therapeutics by 19.7% in the fourth quarter. Turner Investments L.P. now owns 106,080 shares of the biotechnology company’s stock worth $2,832,000 after buying an additional 17,470 shares during the period. Finally, Swiss National Bank bought a new stake in Heron Therapeutics during the fourth quarter worth approximately $1,100,000.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.